---
title: 'The Spectrum of CAR Cellular Effectors: Modes of Action in Anti-Tumor Immunity'
date: '2024-07-27'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39061247/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240727183108&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Chimeric antigen receptor-T cells have spearheaded the field of adoptive
  cell therapy and have shown remarkable results in treating hematological neoplasia.
  Because of the different biology of solid tumors compared to hematological tumors,
  response rates of CAR-T cells could not be transferred to solid entities yet. CAR
  engineering has added co-stimulatory domains, transgenic cytokines and switch receptors
  to improve performance and persistence in a hostile tumor microenvironment, but
  because ...
disable_comments: true
---
Chimeric antigen receptor-T cells have spearheaded the field of adoptive cell therapy and have shown remarkable results in treating hematological neoplasia. Because of the different biology of solid tumors compared to hematological tumors, response rates of CAR-T cells could not be transferred to solid entities yet. CAR engineering has added co-stimulatory domains, transgenic cytokines and switch receptors to improve performance and persistence in a hostile tumor microenvironment, but because ...